Members of the Texas Drug Utilization Review (DUR) Board meet quarterly in Austin to promote safety through an increased review and awareness of outpatient prescribed drugs. Members recommend medical criteria, standards, and educational intervention methods used in Texas Medicaid. The board reviews and approves the therapeutic criteria for prospective and retrospective drug utilization as well as clinical prior authorization criteria. In addition, members also recommend drugs for inclusion in the Medicaid preferred drug list, considering the drug's clinical efficacy, safety, cost-effectiveness, and program benefits.
Please review the written and public testimony procedures prior to submitting information to board members.
By Regular/Overnight Mail
Texas Drug Utilization Review Board (MC-2250)
Texas Health and Human Services
4900 North Lamar Blvd.
Austin, TX 78751
This address is only for issues pertaining to the Texas DUR board. Messages received off-cycle or unrelated to the business of the board are not accepted.
November 8, 2019
Clinical Prior Authorization Assistance Chart Now Available
November 6, 2019
October 2019 Preferred Drug List Recommendations Now Available
November 4, 2019
2020 Drug Utilization Review Board Schedule Available
October 30, 2019
New Indication for Dupixent Clinical Prior Authorization
October 23, 2019
Anticonvulsant Therapeutic Class Update for Oct. DUR Board Meeting
October 4, 2019
July 2019 Preferred Drug List Decisions Now Available